Cardiovascular Profile of Patients with Type 2 Diabetes in France Based on REWIND CVOT Inclusion Criteria: A Real-World Retrospective Study
Résumé
Introduction The REWIND study demonstrated a cardiovascular (CV) benefit of dulaglutide treatment in patients with type 2 diabetes (T2D) with or without established cardiovascular disease (CVD). The current study aims to describe similarities and differences between characteristics of patients with T2D in France and the REWIND population. Methods A retrospective, observational study was conducted in France using primary care IQVIA electronic medical records. Patients aged >= 18 years with at least one clinical visit and/or glucose-lowering agent prescription in 2019 were identified. The percentages of patients aged >= 50 years with established CVD, aged >= 55 years with subclinical CVD or aged >= 60 years with multiple CV risk factors based on REWIND definitions were calculated. Results A total of 63,927 patients with T2D were included. Mean age was 67 years, 93% were aged >= 50 years and 58% were male. The median time since T2D diagnosis was 5.6 years, mean glycated hemoglobin was 7.1% and mean body mass index was 30.4 kg/m(2). Of the patients included in the current study, 59.4% fulfilled REWIND CV criteria; 12.4% of patients were >= 50 years old with established CVD; 9.7% of patients were aged >= 55 years with subclinical vascular disease and 44.7% were aged >= 60 years with >= 2 CV risk factors. Conclusion Almost 60% of this primary care French cohort with T2D fulfilled key REWIND CV criteria, with a lower percentage of patients having established CVD than REWIND participants.